VATSALA BHASKARAN: Open Payments
NPI 1427040401 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$504 in 22 payments from 9 companies in 2025. Trend: 2023 $418 · 2024 $462 · 2025 $504
Food & beverage: $504
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $196 |
| Axsome Therapeutics, Inc. | 1 | $123 |
| Neos Therapeutics, LP | 3 | $49 |
| Neurocrine BioSciences, Inc. | 1 | $28 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $24 |
| Janssen Pharmaceuticals, Inc | 1 | $23 |
| E.R. Squibb & Sons, L.L.C. | 1 | $23 |
| IDORSIA PHARMACEUTICALS US INC | 1 | $22 |
| Collegium Pharmaceutical, Inc. | 1 | $15 |
Products named: VRAYLAR, Auvelity, Adzenys XR-ODT, INGREZZA, CAPLYTA, SPRAVATO, COBENFY, Quviviq.
Industry payments across TX — which companies pay providers there.
